Last reviewed 2026-04-23 · How we verify

Insulin Rinsulin® NPH

Insulin NPH is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

Insulin NPH is a long-acting basal insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.

At a glance

Mechanism of action

NPH (Neutral Protamine Hagedorn) insulin is an intermediate-acting insulin formulation created by complexing insulin with protamine, which slows its absorption and extends its duration of action to 10-16 hours. It works by binding to insulin receptors on muscle, fat, and liver cells, facilitating glucose transport into cells and promoting glycogen synthesis while inhibiting gluconeogenesis. Rinsulin® NPH is a biosynthetic human insulin product manufactured by Geropharm.

Approved indications

• Type 1 diabetes mellitus
• Type 2 diabetes mellitus

Common side effects

• Hypoglycemia
• Injection site reactions
• Weight gain
• Lipodystrophy

Key clinical trials

• Comparative Study of Rinsulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (GEROPHARM LLC, Russia) and Humulin® NPH, Suspension for Subcutaneous Administration, 100 IU/ml (Lilly France, France) Using the Euglycemic Hyperinsulinemic Clamp Method (NA)
• Efficacy and Safety of Insulin Rinsulin® NPH Compared to Humulin® NPH in Type 2 Diabetes Mellitus Patients (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Insulin Rinsulin® NPH CI brief — competitive landscape report
• Insulin Rinsulin® NPH updates RSS · CI watch RSS
• Geropharm portfolio CI